INNOVATE (VATE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on June 12, 2025, with voting available online, by phone, or by mail.
Key 2024 highlights include a $19M rights offering, a $35M capital raise, a 1-for-10 reverse stock split, and strong segment performance in infrastructure, life sciences, and broadcasting.
The company emphasizes active stockholder engagement and transparency, with materials available online and by request.
Voting matters and shareholder proposals
Four proposals: election of four directors, advisory vote on executive compensation (Say on Pay), advisory vote on frequency of Say on Pay (recommended annually), and ratification of BDO USA, P.C. as auditor.
Board recommends voting for all director nominees, for Say on Pay, for annual Say on Pay frequency, and for auditor ratification.
Shareholders of record as of April 21, 2025, are eligible to vote; each share of common and preferred stock (on an as-converted basis) gets one vote.
Board of directors and corporate governance
Board consists of four independent directors: Avram A. Glazer (Chair), Warren H. Gfeller, Brian S. Goldstein, and Amy M. Wilkinson.
All directors are independent under NYSE standards and serve on Audit, Compensation, and Nominating and Governance Committees.
Board leadership is separated between Chairman and CEO; directors are encouraged to attend education programs and annual meetings.
Director nomination process values diversity of experience and skills; stockholders can recommend candidates.
Latest events from INNOVATE
- Q4 2025 revenue up 61.7% to $382.7M, with strong Infrastructure growth and narrowing net loss.VATE
Q4 202526 Mar 2026 - Q2 net income rose to $14.4M as margins improved and Life Sciences posted record sales.VATE
Q2 20242 Feb 2026 - Q3 revenue dropped 35.5% to $242.2M; growth in Life Sciences and Spectrum, but going concern risk remains.VATE
Q3 202416 Jan 2026 - Revenue declined, but Life Sciences and Spectrum grew; debt reduced and backlog remains strong.VATE
Q4 202425 Dec 2025 - Director elections, say-on-pay, and auditor ratification up for vote at June 2025 meeting.VATE
Proxy Filing2 Dec 2025 - Annual meeting adjourned for technical reasons; voting postponed to June 18, 2024.VATE
Proxy Filing2 Dec 2025 - Revenue fell 22.7% to $242M, net loss $22M, Life Sciences grew, major debt refinancing completed.VATE
Q2 202523 Nov 2025 - Revenue dropped 13% to $274.2M; backlog and regulatory wins offset high debt risk.VATE
Q1 202515 Nov 2025 - Q3 revenue up 43% to $347.1M, net loss narrowed, and refinancing triggered asset sales.VATE
Q3 202513 Nov 2025